As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Through this partnership, Alloy gains co-exclusive rights to develop and commercialise iCAR-T and iCAR-NK therapies for cancer treatment. Alloy will also share the technology with its biotech and ...